Impact of Blastocyst Morphological Development and Blastocoele Re-expansion on Pregnancy Outcome After Using REKOVELLE®

Controlled Ovarian Stimulation Clinical Trial

Official title:

The Impact of Frozen - Thawed Blastocyst Morphological Development and Blastocoele Re-expansion on Clinical Pregnancy Outcome After One Controlled Ovarian Stimulation Cycle Using REKOVELLE®

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03697031
• Other study ID #: 000317
• Status: Terminated
• Start date: September 1, 2018
• Est. completion date: December 31, 2020

Study information

• Verified date: October 2021
• Source: Ferring Pharmaceuticals
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this observational study is to examine the development and appearance of embryos before and after freezing following a single controlled ovarian stimulation cycle using REKOVELLE® (follitropin delta) as the recombinant follicular stimulating hormone (rFSH) for controlled ovarian stimulation. The primary objective of the study is to examine how specific factors of embryo development or appearance are related to the chance of becoming pregnant.

The ovarian stimulation protocol with REKOVELLE®, a new rFSH prescribed for ovarian stimulation, is individualised with a dosing regimen that is based on two parameters: the body weight and the level of a hormone, the anti-Müllerian hormone, (AMH), a parameter used to predict how the ovaries will respond to the ovarian stimulation.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 362
• Est. completion date: December 31, 2020
• Est. primary completion date: December 31, 2020
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• Patients undergoing elective single embryo transfer (e-SET) in a frozen embryo replacement (FER) treatment where the frozen blastocyst was obtained from an IVF or intracytoplasmic sperm injection (ICSI) cycle following controlled ovarian stimulation with REKOVELLE® .

• Women are prescribed REKOVELLE® for their IVF or ICSI according to the approved label.

• Morphological measurements and clinical outcomes are available for the fresh embryos obtained from the IVF or ICSI cycle.

• Willing and able to understand Danish or English patient information.

• Willingness and ability to provide written informed consent.

Exclusion Criteria:

• Patients with any contraindication for treatment with REKOVELLE® for controlled ovarian stimulation.

• Patients with contraindication for undergoing assisted reproductive technologies (ART) such as an IVF or ICSI cycle.

• Oocyte donors.

Related Conditions & MeSH terms

• Controlled Ovarian Stimulation

Intervention

Drug:
• Follitropin Delta
The Intervention (solution for injection) is delivered with an injection pen. For women with AMH <15 pmol/L the daily dose is 12 micrograms, irrespective of body weight. For women with AMH =15 pmol/L the daily dose decreases from 0.19 to 0.10 micrograms/kg by increasing AMH concentration. The maximum daily dose for the first treatment cycle is 12 micrograms. For subsequent treatment cycles, the daily dose of REKOVELLE® should be maintained or modified according to the patient's ovarian response in the previous cycle. Based on the ovarian hypo/hyper-response in the previous cycle, the daily dose in the subsequent cycle should be increased (by 25% or 50%) or decreased (by 20% or 33%). The maximum daily dose is 24 micrograms.

Locations

Country	Name	City	State
Denmark	Ciconia, VivaNeo (there may be other sites in this country)	Højbjerg

Sponsors (1)

Lead Sponsor	Collaborator
Ferring Pharmaceuticals

Country where clinical trial is conducted

Denmark, 

References & Publications (1)

Gabrielsen A, Iversen LH, Fedder J, Eskildsen TV, Englund AL, Hansen SR, Pinton P. Pre-Vitrification and Post-Warming Variables of Vitrified-Warmed Blastocysts That Are Predictable for Implantation. J Clin Med. 2023 Oct 6;12(19):6389. doi: 10.3390/jcm1219 — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Clinical pregnancy rate	Clinical pregnancy is defined as at least one intrauterine gestational sac with fetal heart beat at week 7, from frozen thawed blastocysts. The correlation between morphological parameters (blastocyst score, timelapse score, blastocoele re-expansion) and clinical pregnancy rate will be assessed.	7 weeks after each embryo transfer
Secondary	Cumulative clinical pregnancy rate	The cumulative clinical pregnancy rate will be calculated based on all participants included in the study and all clinical pregnancies recorded from fresh and frozen-thawed blastocyst transfers as the fraction of participants with at least one positive clinical pregnancy. The cumulative pregnancy rate will be plotted versus transfer number and versus time from start of REKOVELLE® treatment.	Up to 24 months
Secondary	Positive ßhCG result (blood or urinary pregnancy test)		Up to 24 months
Secondary	Use of the algorithm-based individualized dosing regimen with REKOVELLE®	Use of the Ferring developed dosing app for the daily dose calculation. The daily dose is calculated with body weight in kilograms or pounds and AMH serum level in pmoL/L or ng/ml to define the daily dose of REKOVELLE® in micrograms.	At the day of the consultation visit where the daily dose of REKOVELLE® is decided
Secondary	Daily dose of REKOVELLE® administered	Daily dose of REKOVELLE® in micrograms is recorded.	From day 1 up to day 20 of REKOVELLE® stimulation
Secondary	Number of days of treatment with REKOVELLE®		From day 1 up to day 20 of REKOVELLE® stimulation
Secondary	Day of REKOVELLE® stimulation start	The time point of the start of the stimulation is decided at the discretion of the investigator.	At the day of the first REKOVELLE® injection during the ovarian stimulation treatment
Secondary	Day of REKOVELLE® stimulation end	The time point of the end of the stimulation is decided at the discretion of the investigator.	At the day of the last REKOVELLE® injection during the ovarian stimulation treatment
Secondary	Any deviation in REKOVELLE® administration	REKOVELLE® should be used according to the approved label, any possible deviations such as different starting dose or dose adjustment during stimulation will be recorded and analyzed.	From day 1 up to day 20 of REKOVELLE® stimulation